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Abstract
Objectives—We explored whether state laws allowing pharmacists to administer human 
papillomavirus (HPV) vaccinations to adolescents are associated with a higher likelihood of HPV 
vaccine uptake.
Methods—We examined provider-reported HPV vaccination among 13 to 17 year olds in the 
National Immunization Survey-Teen: 2008–2014 for girls (N=48,754) and 2010–2014 for boys 
(N=31,802). Outcome variables were HPV vaccine initiation (≥ 1 dose) and completion (≥ 3 
doses). The explanatory variable of interest was a categorical variable for the type of pharmacist 
authority regarding HPV vaccination for adolescents (< 18 years) in the state: not permitted 
(reference), by prescription, by collaborative practice protocol, or independent authority. We ran 
separate difference-in-difference regression models by sex.
Results—During 2008–2014, 15 states passed laws allowing pharmacists to administer HPV 
vaccine to adolescents. Pharmacist authority laws were not statistically significantly associated 
with increased HPV vaccine initiation or completion.
Conclusions—As currently implemented, state laws allowing pharmacists to administer HPV 
vaccine to adolescents were not associated with uptake. Possible explanations that need further 
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research include restrictions on pharmacists’ third-party billing ability and the lack of promotion 
of pharmacy vaccination services to age-eligible adolescents.
Keywords
human papillomavirus; HPV vaccine; vaccination laws; pharmacist; pharmacy practice; 
difference-in-difference
INTRODUCTION
Human papillomavirus (HPV) is the most common sexually-transmitted infection in the 
United States (U.S.), causing around 300,000 new cases of genital warts and 26,000 cancers 
(anal, cervical, oropharyngeal, penile, vaginal, and vulvar) each year in men and women.1 
The Advisory Committee on Immunization Practices (ACIP) has recommended routinely 
vaccinating all girls ages 11–12 with HPV vaccine since 2007. Catch-up vaccination is 
recommended for females aged 13 to 26 years who have not been previously vaccinated. 
Permissive recommendations were added for boys in 2009 and routine recommendations for 
boys came in 2011. The recommended age for boys is 11 to 12 years with catch-up 
vaccination recommended for males aged 13 to 21 years.2 Despite the vaccine’s safety and 
effectiveness, HPV vaccination coverage is far below the national objective set by Healthy 
People 2020. In 2014, completion of the three-dose series among adolescents ages 13 to 17 
was only 40% for girls and 22% for boys.3 HPV vaccination coverage also lags far behind 
childhood and other adolescent vaccines.3 The reasons for underuse of HPV vaccine are 
complex as several factors affect vaccine uptake.4,5
Recently, the President’s Cancer Panel and the National Vaccine Advisory Committee 
(NVAC) recommended expanding HPV vaccination to pharmacies as one strategy to 
improve vaccination coverage.6 Pharmacies have particular advantages that make them 
appealing for HPV vaccination for adolescents. An estimated 250 million visits are made to 
pharmacies each week, and around 93% of Americans live within 5 miles of a pharmacy,7 
exhibiting the likelihood of high accessibility among the U.S. adolescent population.8 
Pharmacies also have longer hours of operation and typically do not require an appointment 
unlike most medical clinics.9 Additionally, one study characterizing vaccination visits at a 
national pharmacy chain showed that over 6 million total vaccine doses (85% influenza, 
15% other vaccines) were administered to adults over the one year study period, providing 
further evidence of the capacity that pharmacies are able to provide in vaccination efforts.10 
Another study found that pharmacist provision of influenza vaccination increased among 
adolescents after they were given the legal authority in Oregon.11 With the success of 
vaccination of adults in pharmacies over the past two decades, the President’s Cancer Panel 
and NVAC’s recommendation for expanding HPV vaccinations to pharmacies seems 
promising. However, we know of no published studies quantifying the use of pharmacies for 
HPV vaccinations among age-eligible adolescents.
Independent of such recommendations, many states have expanded pharmacists’ vaccination 
authority for adolescents, including HPV vaccination.9 Pharmacists’ vaccination authority to 
administer vaccines is typically one of four types: not permitted, by prescription, by 
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collaborative practice protocol, or independent authority. In states where vaccination is not 
permitted, pharmacists may not administer the vaccine under any circumstances. In 
prescription-only states, pharmacists are allowed to administer the vaccine only to 
adolescents who present a prescription from a prescriber (e.g., physicians). In states with 
collaborative practice protocol laws, pharmacists may administer the vaccine to patients of a 
prescriber upon the signing of a supervision agreement with that prescriber, which may, 
depending on the state, include standing orders, protocols, collaborative agreements, or 
similar documents. In states where pharmacists have independent authority to administer 
HPV vaccines to adolescents, pharmacists may administer the vaccine without prior 
approval from a prescriber.
While the legal authority to administer HPV vaccine is a minimum requirement to meet the 
policy recommendations, effective use of these services will depend on a host of factors 
including consumer awareness of vaccination services in pharmacies and reimbursement 
policies. The population impact of expanding pharmacists’ practice to administer HPV 
vaccine to adolescents is unknown. Our study explores whether state laws that allow 
pharmacists to administer HPV vaccine to adolescents were associated with higher 
likelihood of HPV vaccination.
METHODS
Data sources
The National Immunization Survey-Teen (NIS-Teen) is a national survey administered every 
year by the Centers for Disease Control and Prevention (CDC) and the National Center for 
Health Statistics to estimate current vaccine coverage for adolescents aged 13 to 17 years. 
These data are collected in two phases: 1) telephone interview of a random sample of U.S. 
households and 2) vaccination history from current medical provider via mail. 
Sociodemographic information, along with vaccination beliefs and attitudes, behaviors, and 
the teen’s vaccination history are collected from the telephone interview. In the second 
phase, with the parent or guardian’s permission, NIS-Teen contacts the adolescent’s primary 
care provider by mail, asking them to complete and return a provider verified vaccination 
record (Provider-Immunization History Questionnaire). We examined HPV vaccination 
within the provider-reported sample for years following recommendation by ACIP: 2008 
through 2014 for girls and 2010 through 2014 for boys. Response rates for the provider 
information range from 52.3% to 62.0% over the study years.12
We generated analytic vaccination law data directly from each state’s pharmacy practice 
statutes. First, one of the authors (WAC, lawyer) identified the pharmacy practice law 
pertaining to pharmacist-administered vaccinations using the Robert Wood Johnson 
Foundation LawAtlas database and LexisNexis. Next, a second author (PDS, licensed 
pharmacist) verified the state’s vaccination law and coded the law based on pharmacist’s 
practice authority to administer HPV vaccine to adolescents. This initial coding was revised 
by one of the authors (WAC) and any discrepancies were resolved between authors (WAC 
and PDS). We then cross-referenced our coding schema with available information on this 
topic from the American Pharmacists Association and the National Alliance of State 
Pharmacy Associations State Immunization Authority Annual Survey. Laws in effect in the 
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50 states and the District of Columbia between January 1, 2008 and December 31, 2014 
were included in analyses.
Measures
Outcome variables were indicators for HPV vaccine series initiation (≥ 1 dose) and 
completion (≥ 3 doses) as reported by a health care provider in NIS-Teen. The explanatory 
variable of interest was a categorical variable for the type of pharmacist authority regarding 
HPV vaccination for age-eligible adolescents: not permitted (reference), by prescription, by 
collaborative practice protocol, or independent authority. The coding scheme was developed 
from an adapted definition that characterized the level of vaccination authority given to 
pharmacists.9 We also analyzed an alternate coding with a single indicator for state-years 
with any type of pharmacist authority to administer HPV vaccinations to adolescents.
Demographic and health characteristics for the index child included sex; indicators for each 
year of age; race and ethnicity (Non-Hispanic white, Non-Hispanic black, Hispanic, or 
other/unspecified); number of health care visits in the past year (range 1 to 9); receipt of 
influenza vaccination in the current season, receipt of Tdap and meningococcal vaccinations; 
and health insurance status (private, Medicaid, other public insurance, uninsured, or 
unspecified or missing). At the parental level, we included mother’s education (less than 
high school, high school diploma, some college, or college degree or higher). Finally, for 
household characteristics, we assessed household income (≤ $25,000, $25,001–$50,000, 
$50,001–$75,000, or ≥ $75,001, household size (range 2 to 8 or more), and number of 
children in the household (1, 2 or 3, or 4 or more).
Statistical analysis
We estimated difference-in-differences linear probability models to identify the effect of 
changes in state-level pharmacist vaccination authority on individual HPV vaccination 
outcomes. The difference-in-differences approach compares changes in HPV vaccination 
outcomes before and after a state enacted a law to changes over the same time period in 
states that did not enact a law. We ran separate models for boys (N=31,802) and girls 
(N=48,754), HPV vaccine initiation and completion outcomes, and for both measures of 
pharmacist authority laws (8 total models). In the main analyses, states with pharmacist 
provision laws for the entire study period (k=14) were excluded because we could not 
observe differences in HPV vaccination rates pre- and post-enactment. In sensitivity 
analyses, we also estimated the models using the full sample of adolescents in all states and 
the District of Columbia.
All models adjusted for indicator variables for state and year, state-specific time trends (i.e., 
interactions between state indicators and year as a continuous variable), state-level school 
entry requirements for meningococcal13 and Tdap vaccines,14 and the variables listed above 
in Measures. Analyses were weighted using the provider-reported sample weights in NIS-
Teen and standard errors were clustered by state. We conducted our analyses using Stata 
version 14.0 (College Station, TX). All statistical tests were two-tailed with a critical alpha 
equal to 0.05. The study was deemed not human subjects research by the University of North 
Carolina at Chapel Hill Institutional Review Board.
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RESULTS
The HPV vaccine initiation rate in our analysis sample was 38.0% (48.5% female and 19.7% 
male); the completion rate was 22.4% (30.6% female and 8.3% male) (Table 1). Over three 
quarter of respondents lived in state-years that did not have any pharmacist vaccine authority 
(76.5%). Pharmacist vaccination authority through a protocol was the most common type of 
provision (14.9%), followed by prescription only (5.8%) and independent authority (2.8%).
Between 2008 and 2014, 15 states passed laws allowing pharmacists to administer HPV 
vaccine to adolescents, 22 states did not have pharmacist provision laws and 14 states had 
pharmacist provision laws for the entire period. Figure 1 shows unadjusted HPV vaccination 
rates over time with each line representing a different group of states defined by the effective 
date of the pharmacist vaccination authority law, including a group for states that never 
passed such laws. No states passed pharmacist authority laws in 2010. Figures 1 and 2 
include separate panels for initiation vs. completion of the HPV vaccine for girls and boys 
respectively. In each series, “X” indicates the year of passage of the law. Overall, there was a 
general upward trend in HPV vaccination for each sex, outcome, and group of states. States 
that passed pharmacist provision laws prior to our analysis period (2008 for girls and 2010 
for boys), tended to have higher initiation rates than states that never passed laws or passed 
laws later. There is no indication that HPV vaccination rates improved in the year of, or 
after, enactment separate from the general trends. Such an effect would have been indicated 
by a sustained upward shift of the trend beginning at the “X.”
The difference-in-difference analysis that categorized the pharmacist authority laws by type 
showed no statistically significant association between vaccination authority type and HPV 
vaccination (Table 2). This null result was found for girls and boys and for initiation and 
completion outcomes. The lack of statistical significance was a result of large standard 
errors (and therefore wide confidence intervals). Across specifications, HPV vaccination was 
more likely the older the adolescent, for Hispanics, the higher the engagement with the 
health care system (i.e., more visits, receipt of other vaccines), for Medicaid beneficiaries 
(except for completion among boys), for adolescents’ mothers with less than high school 
education (except for completion among girls), and for households with lower income.
When pharmacist vaccination authority was collapsed into a single indicator for any type of 
law, there was still no significant association between the law and HPV vaccination 
(Appendix Table A1). Nor did the results change when adolescents from the 14 states that 
passed pharmacist vaccination authority laws prior to the analysis sample were added back 
to the sample (Appendix Table A1).
DISCUSSION
To our knowledge, this is the first study to evaluate the potential impact of state laws that 
allow pharmacist-administered HPV vaccination on national HPV vaccination coverage 
among adolescents. Our results suggest that, as currently implemented, these state laws were 
not associated with HPV vaccine coverage rates, regardless of the type of authority. There 
are several potential explanations for why we find no association between these laws and 
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vaccine uptake, including the lack of financial incentive for pharmacists to administer HPV 
vaccine, poor promotion of adolescent vaccination services in pharmacies, and the 
possibility that families are merely substituting across settings from physician offices to 
pharmacies.
The largest structural barrier to pharmacists administering HPV vaccine is that many 
insurers do not consider pharmacies in-network providers for HPV vaccination.15,16 A 
pharmacy can bill insurance providers for vaccines administered to patients if the patients’ 
pharmacy benefits include vaccines or the insurance provider recognizes the pharmacy as a 
medical provider. Patients may have to pay out-of-pocket for vaccines from a pharmacy if 
their insurance does not cover pharmacy-delivered vaccines or their insurance provider 
considers the pharmacy out-of-network. The lack of recognition by insurance plans creates 
less incentive for pharmacists to stock HPV and other adolescent vaccines. A recent survey 
of state pharmacy association spokespersons showed that less than 25% of pharmacies 
routinely carried adolescent vaccines (defined as Tdap, HPV, meningococcal, and Hepatitis 
B vaccines), whereas over 50% routinely carried influenza vaccine, a commonly covered 
vaccine.17
Additionally, limited reimbursement through federal programs also hampers pharmacy 
involvement in HPV vaccination. The Vaccines for Children (VFC) program provides free 
vaccines to children who otherwise would not have the ability to pay for the vaccinations. 
This program is operated through each state’s health department and Medicaid program. Not 
all states recognize pharmacists as Medicaid providers, greatly limiting their participation in 
vaccination efforts for publicly insured children.18 Lack of participation by pharmacies in 
adolescent vaccination services for state-managed federal programs like VFC may, in part, 
explain why our analyses did not show a significant change in vaccine uptake after the 
passage of pharmacist authority laws during the study period. The NVAC recommends 
removing barriers to paying for HPV vaccines, including payment for vaccines provided 
outside of the medical home and by out-of-network or non-physician providers.19
Another explanation is the lack of promotion of the availability of HPV and other adolescent 
vaccines in pharmacies. Given the demonstrated success of adult vaccination in 
pharmacies,18 it is reasonable to think that similar approaches to increasing vaccine uptake 
would work for adolescents and their parents.20 Promotion of the advantages of pharmacy 
vaccination services, including longer and more convenient hours compared to traditional 
physician offices10 and no need for appointments16 may appeal to parents of vaccine-eligible 
adolescents. Many pharmacies already implement low-cost promotion strategies that could 
be adopted for HPV vaccine, such as advertising on interior and exterior store signage, 
receipts, and shopping bags.
One more explanation for the lack of association between vaccination rates and the 
pharmacist authority laws in our analysis is that the laws would have to encourage 
vaccination among adolescents who would have otherwise not received HPV vaccination. 
Families merely switching from vaccination in physician offices to pharmacies would not 
necessarily increase the overall uptake rate. The publicly available NIS-Teen does not 
contain information on the source of vaccine (e.g., pharmacies vs. medical clinics) and we 
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are not aware of published studies on the use of pharmacies for vaccinations by children and 
adolescents. As such, we do not know the extent to which parents perceive pharmacies as 
viable venues for getting vaccines. Evidence suggests there may be benefits to pharmacist 
provision of vaccines apart from increasing the uptake rate; for example, pharmacist-
delivered influenza vaccine is less costly relative to physician offices.21
In-pharmacy programs for adult vaccinations (e.g., influenza and shingles) could serve as a 
template for adolescent vaccines such as HPV. Currently, all 50 states and the District of 
Columbia, allow pharmacists to administer vaccines to adults. Data from the American 
Pharmacists Association showed that pharmacists provide adult vaccination services in 86% 
of community pharmacies, so pharmacists have an active role as vaccine providers in the 
U.S.22 However, this is not the case for HPV vaccination. State pharmacy practice laws, as 
currently implemented, underutilize the capacity of more than 250,000 trained pharmacists 
to administer vaccines and fully contribute to public health.23
This study has notable strengths, including a nationally representative sample from the NIS-
Teen, provider-reported vaccinations to limit recall and self-reporting bias, the ability to 
examine different types of pharmacist authority laws, and an analytic design that accounts 
for state-specific time trends in HPV vaccination. However, our study is limited by several 
key factors. First, the estimated standard errors for the coefficients on the state laws were 
large. Therefore, we did not have enough statistical power to rule out relatively large effects 
of the laws. For example, the 95% confidence interval for the presence of any type of law on 
initiation among girls ranged from negative one percentage point to seven percentage points 
(author’s calculation from Appendix Table A1). Second, we did not have data on pharmacist 
reimbursement policy among state Medicaid programs and major insurers, which could 
moderate the effect of these laws on HPV vaccination. Finally, we could not include other 
patient-level factors known to affect HPV vaccination, such as the strength of physician 
recommendation to vaccinate.24–26
CONCLUSION
The passage of pharmacist authority laws is a necessary step to increase access to HPV 
vaccination but not sufficient on its own to increase HPV vaccine uptake among adolescents. 
Our study may provide a starting point for further research to identify key components 
enabling vaccination laws, and public health laws more generally, to be effective in practice. 
Of note, creating new reimbursement mechanisms could help sustain pharmacy vaccination 
programs and create an additional revenue sources for community pharmacies looking to 
expand their services. Additionally, strategic promotion of adolescent vaccinations in total, 
rather than HPV vaccine alone, during summer months when adolescent vaccine uptake is 
greatest, may also be important to increase parents’ awareness of the availability of 
vaccination services outside of the traditional medical home. While pharmacies are not 
intended to replace the medical home, they can play an integral role within the 
“immunization neighborhood” to meet the needs of patients and the communities served.23
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Figure 1. HPV Vaccine Initiation and Completion Rates Among Adolescent Girls by Year of 
Pharmacist Authority Law, NIS-Teen, 2008–2014
a - States included in each group for girls: <=2008 - AL, AK, CA, CO, LA, MI, MO, NE, 
NV, ND, PA, SD, WA, WY; 2009 - AZ, GA, OK, TX; 2011 - AR, ID, KY, MS, OR; 2012 - 
UT; 2013 - DE, IL, IN, IA, WI; Never - CT, DC, FL, HI, KS, ME, MD, MA, MN, MT, NH, 
NJ, NM, NY, NC, OH, RI, SC, TN, VT, VA, W
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Figure 2. HPV Vaccine Initiation and Completion Rates Among Adolescent Boys by Year of 
Pharmacist Authority Law, NIS-Teen, 2010–2014
b - States included in each group for boys <=2010 - AL, AK, AZ, CA, CO, GA, LA, MI, 
MO, NE, NV, ND, OK, PA, SD, TX, WA, WY; 2011 - AR, ID, KY, MS, OR; 2012 - UT; 
2013 - DE, IL, IN, IA, WI; Never - CT, DC, FL, HI, KS, ME, MD, MA, MN, MT, NH, NJ, 
NM, NY, NC, OH, RI, SC, TN, VT, VA, WV
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Table 1
Sample Vaccination and Demographic Characteristics, NIS-Teen, 2008–2014
N Weighted % Weighted Mean Standard Deviation
HPV vaccination
 Initiation (≥ 1 doses) 31,113 38.0 – –
  Female 24,676 48.5 – –
  Male 6,437 19.7 – –
 Completion (≥ 3 doses) 18,913 22.4 – –
  Female 16,147 30.6 – –
  Male 2,766 8.3 – –
Vaccination authority type
 No authority 61,155 76.5 – –
 Prescription only 4,199 5.8 – –
 Protocol 11,756 14.9 – –
 Independent authority 3,905 2.8 – –
School entry requirements
 Tdap vaccination 53,713 68.3 – –
 Meningococcal vaccination 23,714 25.8 – –
Child characteristics
Sex
 Male 31,949 36.7 – –
 Female 49,066 63.3 – –
Age
 13 years old 16,338 19.6 – –
 14 years old 16,814 20.1 – –
 15 years old 16,400 20.8 – –
 16 years old 16,577 20.9 – –
 17 years old 14,886 18.6 – –
Race/ethnicity
 Non-Hispanic White 55,463 60.1 – –
 Non-Hispanic Black 8,162 16.0 – –
 Hispanic 10,452 16.4 – –
 Other or Unspecified 6,938 7.5 – –
Health care visits 80,556 – 2.83 0.01
Receipt of Influenza vaccine (current season) 3,722 3.9 – –
Receipt of Tdap vaccine 69,120 85.1 – –
Receipt of meningococcal vaccine 55,644 67.5 – –
Insurance
 Private 46,750 50.6 – –
 Medicaid 21,095 31.9 – –
 Other public insurance 8,518 9.9 – –
 Uninsured 3,773 6.4 – –
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N Weighted % Weighted Mean Standard Deviation
 Unspecified or missing 879 1.2 – –
Parent characteristics
Mother's education
 Less than high school 7,573 11.9 – –
 High school diploma 15,127 25.7 – –
 Some college 22,444 26.6 – –
 College degree or higher 35,871 35.9 – –
 Household characteristics
Income
 Less than 25,000 13,302 22.0 – –
 $25,001 – $50,000 14,678 20.5 – –
 $50,001 – $75,000 12,736 15.0 – –
 $75,0000 or more 35,651 35.4 – –
 Unspecified or missing 4,648 7.1 – –
Household size 81,015 – 4.40 0.01
Number of children 81,015 – 1.80 0.00
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